Rigel (RIGL) Q2 Revenue Jumps 176%
Rigel Pharmaceuticals (NASDAQ:RIGL), a biopharmaceutical company known for developing and selling treatments for cancer and rare blood disorders, released its second quarter 2025 results on August 5, 2025. The most significant takeaway from the earnings release was that GAAP revenue and net income far exceeded Wall Street estimates. Revenue (GAAP) reached $101.7 million, beating the $88.95 million GAAP consensus, while earnings per share (EPS, GAAP) came in at $3.28 compared to the expected $2.58. These numbers show a strong improvement over last year’s quarter, as reported on a GAAP basis, with a steep jump in both sales and earnings (GAAP). The results reflect robust demand for Rigel's approved treatments and a key one-time spike in collaboration revenue (GAAP), making for an exceptional quarter overall.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Rigel Pharmaceuticals focuses on discovering, developing, and bringing to market new therapies for cancer and rare blood disorders. Its main revenue comes from selling its three U.S. Food and Drug Administration (FDA)-approved drugs: TAVALISSE (a tablet for chronic immune thrombocytopenia, a bleeding disorder), REZLIDHIA (a capsule for a rare form of leukemia called IDH1-mutant acute myeloid leukemia), and GAVRETO (a capsule for RET fusion-positive lung and thyroid cancers).
Source Fool.com
